SESSION TITLE: Lung Cancer Posters I
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PM
PURPOSE: While the recent NLST study demonstrated that screening for lung cancer by low-dose CT leads to a significant reduction of lung cancer mortality, biomarkers are needed to 1) determine which of the frequently detected lung nodules on CT scan are malignant and 2) how to further define the large high-risk population that would be eligible for CT screening to increase its efficacy. The Detection of Early lung Cancer Among Military Personnel (DECAMP) consortium is a DOD-funded program to develop and validate molecular biomarkers to address these two clinical needs among military personnel and veterans who are at increased risk by virtue of higher exposure to tobacco smoke and other carcinogens.
METHODS: The DECAMP consortium seeks to address these gaps in the early detection of lung cancer via two clinical studies. First, the consortium will validate a number of airway and blood-based molecular biomarkers that can distinguish benign vs. malignant diseases among smokers with indeterminate pulmonary nodules found on CT chest. We will recruit 500 smokers with indeterminate pulmonary nodules (7mm-25mm) on chest CT who will undergo fiberoptic bronchoscopy on enrollment and will be followed for 2 years until a final diagnosis is made. Our second study will develop and test relatively non-invasive molecular markers in the airway and blood that can identify those smokers at highest risk for developing cancer. We will recruit 1000 high-risk smokers who will be followed for approximately 4 years for development of lung cancer, all of whom will undergo low-dose chest CT and non-invasive biospecimen collection annually for the first three years as well as have bronchoscopy performed upon enrollment and at 2 years of follow-up.
RESULTS: To date, 86 subjects have been enrolled in the nodule study. A subset of these with complete demographics (n=52) have an average age of 66.2 with 79% being male, mean pack/years of 72.9 and 79% are active cigarette smokers. The mean FEV1 is 66.2% and 48% have at least moderate COPD. The average nodule size is 1.1cm.
CONCLUSIONS: The DECAMP Consortium has been established in order to develop and validate early detection biomarkers for lung cancer.
CLINICAL IMPLICATIONS: The DECAMP consortium will also establish a unique biological (including bronchial airway brushings and biopsies, nasal and buccal brushings, blood, urine and sputum), clinical and imaging repository from patients at 4 military treatment facilities and 7 VA hospitals to support these 2 studies and future correlative studies.
DISCLOSURE: Marc Lenburg: Consultant fee, speaker bureau, advisory committee, etc.: Allegro Diagnostics Avrum Spira: Shareholder: Allegro Diagnostics The following authors have nothing to disclose: Ali Jiwani, Emily Maple, Mitchell Schnall, Irene Mahon, Charles Apgar, Robert Browning, Kenneth More, Michael Morris, John Parrish, Charles Atwood, John Battaile, Eric Garshick, Constantine Gatsonis, Ronald Goldstein, Robert Kieth, Mary Reid, Daniel Remick, Anil Vachani, Ignacio Wistuba, Pierre Massion, Steven Dubinett, David Elashoff, Fenghai Duan
No Product/Research Disclosure Information